MacroCure currently manufactures and markets its lead product, CureXcell™, in Israel for hard-to-heal wound treatment. The cell therapy company has its regulatory strategy in place for market approval in North America and Europe. CureXcell™, a cell based therapy for hard to heal wounds, to restore the wound healing process (You Tube video from MacroCure)
Archives for May 2012
New data among 200 Lucentis® abstracts at ARVO show low number of injections with Novartis drug required to achieve and maintain vision gains over 3 years in AMD and DME patients (Novartis)
Structured self-monitoring of blood glucose leads to significant increases in self-confidence and autonomous motivation associated with diabetes self-management. Changes in self-confidence are linked to changes in glycemic control and share a time-concordant relationship (Diabetes Research and Clinical Practice)
The current data demonstrate that early type 2 diabetes is associated with an increase in the SERCA/PLB ratio and that insulin directly stimulates SERCA expression and relaxation velocity. These results underline the important role of insulin and calcium handling proteins in the cardiac adaptation process of type 2 diabetes mellitus contributing to cardiac remodeling and show the important role of PI3-kinase- kt-SERCA2a signaling cascade (Cardiovascular Diabetology)
Our estimates suggest prevalence of severe hypoglycaemia attended by the emergency services is high in younger age groups and lower for older age groups, although the absolute numbers of severe events in older age groups contribute substantially to the overall costs of providing emergency assistance for hypoglycaemia (Diabetic Medicine)
Trials of metformin (MF) as an anti-cancer drug have recently begun, enhancing its reputation as a ‘wonder-drug’, effective over a spectrum of life-threatening diseases whilst being highly cost-effective. The cancer story began following reports (wildly exaggerated, in my view) that insulin glargine increased the risk of cancer but this was not seen in patients taking concomitant MF. Allied to its beneficial impact on cardiovascular (CV) outcomes, MFs first-line position in ALL diabetes guidelines seems to have been consolidated. But how strong is the evidence?